Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDED AND RESTATED CLINICAL COLLABORATION AND SUPPLY...Clinical Collaboration and Supply Agreement • May 9th, 2023 • Olema Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This AMENDED AND RESTATED CLINICAL COLLABORATION AND SUPPLY AGREEMENT (the “Agreement”) is made and entered into effective as of January 13, 2022 (the “Effective Date”) by and between Olema Pharmaceuticals, Inc., a Delaware corporation, having a place of business at 665 3rd St, San Francisco, CA 94107 (“Olema”), and Novartis Institutes for BioMedical Research, Inc., a Delaware corporation, having a place of business at 181 Massachusetts Avenue, Cambridge, MA 02139 (“Novartis”). Olema and Novartis are sometimes individually referred to in this Agreement as a “Party” and collectively as the “Parties.”
March 8, 2023 Kinney Horn VIA EMAIL Dear Kinney:Separation and Consulting Agreement • May 9th, 2023 • Olema Pharmaceuticals, Inc. • Pharmaceutical preparations
This letter sets forth the substance of the separation and consulting agreement (the “Agreement”) that Olema Pharmaceuticals, Inc. (the “Company”) is offering to you to aid in your employment transition.
March 21, 2023 Cyrus Harmon VIA EMAIL Dear Cyrus:Separation Agreement • May 9th, 2023 • Olema Pharmaceuticals, Inc. • Pharmaceutical preparations
This letter sets forth the substance of the separation agreement (the “Agreement”) that Olema Pharmaceuticals, Inc. (the “Company”) is offering to you to aid in your employment transition.
